- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00162487
Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation
Evaluation of β2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration
Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour.
The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies.
The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Recruiting
- Hadassah Medical Organization
-
Principal Investigator:
- Yoseph Caraco, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients regularly attending the nephrological clinic or the dialysis unit
- persistent potassium concentration above 5 mEq/L
Exclusion Criteria:
- Patients suffering from active ischemic heart disease
- Patient with a recent history of arrhythmia
- Patients treated regularly with ß blockers
- Patients treated regularly with salbutamol or other ß2AR agonists
- Patients suffering from persistent tachycardia (pulse > 100 beats/min)
- Patients who are hemodynamically unstable
- Patients suffering from any acute illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The extent of decrease in plasma potassium concentration
|
The extent of increase in plasma glucose concentration
|
Plasma concentration of albuterol
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yoseph Caraco, MD, Hadassah Medical Organization
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Water-Electrolyte Imbalance
- Kidney Failure, Chronic
- Hyperkalemia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Reproductive Control Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
Other Study ID Numbers
- yc19556-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
University of PennsylvaniaTeleflex; Arrow InternationalCompletedRenal Failure Chronic Requiring Hemodialysis | Chronic Renal InsufficiencyUnited States
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownChronic Renal Failure With HemodialysisChina
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States
-
Esraa Ahmed MohamedUnknownEvaluations of Sexual Dysfunction of Female in Chronic Renal Failure
-
Janssen Cilag S.A.S.TerminatedAnemia | Renal Failure, Chronic Renal Failure
Clinical Trials on Albuterol (1,200 μg) through metered-dose inhaler
-
Bond Avillion 2 Development LPCompletedAsthmaUnited States, Germany, Ukraine, Serbia, Czechia, Argentina, Slovakia
-
Bond Avillion 2 Development LPCompletedAsthmaUnited States, Canada, Germany, Spain, South Africa, United Kingdom, Slovakia, Argentina, Ukraine, Serbia, Czechia
-
Philips RespironicsCompleted
-
Hasan Kalyoncu UniversityNot yet recruitingAsthma | Patient EducationTurkey
-
Organon and CoCompleted
-
AstraZenecaCompleted
-
Bond Avillion 2 Development LPCompleted
-
AstraZenecaRecruiting
-
Actavis Inc.Teva Pharmaceuticals USACompleted